Home  Research About R&D
|
|
We want to push the boundaries of medical science for the benefit of patients around the world
|  | Medical need
The medical need is growing with the increasing and aging populations. The world population has doubled in the last 50 years from three billion to six billion and is expected to reach nine billion by 2050. Small molecules, biologicals and vaccines
We have broadened our capability to address disease mechanisms with the addition of our world-class biologics and vaccines unit MedImmune.
Disease areas
We focus our resources on six therapy areas where we believe our skills and resources can make the most difference. These areas include some of the world's most serious illnesses and together represent a major worldwide burden of disease: Follow links above to read more about our product pipeline in each area. Global reach We employ around 13,000 people at 17 principal R&D centres in 8 countries.
In 2007, our R&D spend totalled more than $5 billion | Main R&D facilities | Small molecule research sites:
UK: Alderley Park, Macclesfield, Charnwood and London (Arrow Therapeutics)
Sweden: Lund, Mölndal and Södertälje
US: Boston MA and Wilmington DE
Canada: Montreal QC
France: Reims
India: Bangalore
China: Shanghai
Japan: Osaka (Clinical development)
MedImmune biologics and vaccines research sites:
US: Gaithersburg MD and Mountain View CA
UK: Cambridge
|
|
|
|
|